Abstract
In this issue of Blood, Herman et al elucidate the in vivo effects of ibrutinib (a BTK inhibitor) in various disease compartments of patients with chronic lymphocytic leukemia (CLL).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3215-3216 |
| Number of pages | 2 |
| Journal | Blood |
| Volume | 123 |
| Issue number | 21 |
| DOIs | |
| State | Published - May 22 2014 |
| Externally published | Yes |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology